Members of the US Advisory Committee on Immunization Practices favor harmonizing recommendations for use of Pfizer’s and GSK’s respective pentavalent meningococcal vaccines after the expected approval of the GSK product in February 2025.
Pfizer, GSK Pentavalent Meningococcal Vaccine Recommendations Should Be Harmonized, ACIP Says
The US CDC committee appears on track to recommend GSK’s five-in-one vaccine when use of both a quadrivalent vaccine and a separate meningitis B vaccine are indicated at the same visit, the approach adopted for Pfizer’s Penbraya.
